Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by widespread fibrosis affecting the skin, internal organs, and vasculature. Yet, most available therapies for SSc are organ-specific, such as proton pump inhibitors for gastroesophageal reflux; angiotensin converting enzyme inhibitors for renal crisis; several vasodilating therapies such as phosphodiesterase-5 inhibitors, endothelin receptor antagonists, and prostacyclin analogues for pulmonary arterial hypertension. However, there are currently no systemic, disease modifying therapies available for the treatment of this condition and the outcomes remain poor.

We invite authors to submit original research articles, review articles, or case reports describing emerging therapies for SSc. Manuscripts may focus on any form of therapy for SSc including nonmedical therapies, such as physical therapy or complementary medicine approaches; medications targeting specific organs/symptoms; disease modifying therapies; immunomodulatory treatments; antifibrotic agents; or biologic therapies. Manuscripts can describe preclinical, clinical, or translational studies related to new therapies for SSc. Potential topics include, but are not limited to:

• Preclinical evaluation of novel therapies in animal models of SSc
• Early and late phase clinical trial safety and/or efficacy results
• Translational studies identifying novel therapeutic targets for SSc
• Case reports or case series of SSc patients treated with available biologic or immunomodulatory agents

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/ijr/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: